This study evaluated the diagnostic performance of plasma biomarkers for Alzheimer's disease (AD) using an automated platform. In a cohort of 74 consecutive patients, plasma p-Tau181 levels were significantly higher in AD compared to non-AD groups and showed correlation with cerebrospinal fluid biomarkers. Plasma p-Tau181 demonstrated high diagnostic accuracy for AD, with an area under the curve of 0.854. The findings suggest that plasma biomarkers, particularly p-Tau181, could improve the accessibility and efficiency of AD diagnostics in clinical settings, offering a less invasive and cost-effective alternative to traditional methods.
BlennowKGalaskoDPerneczkyR, et al.The potential clinical value of plasma biomarkers in Alzheimer's disease. Alzheimers Dement2023; 19: 5805–5816.
2.
SchindlerSEGalaskoDPereiraAC, et al.Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO initiative on Alzheimer's disease. Nat Rev Neurol2024; 20: 426–439.
3.
TeunissenCEVerberkIMWThijssenEH, et al.Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol2022; 21: 66–77.
4.
KarikariTKPascoalTAAshtonNJ, et al.Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol2020; 19: 422–433.
5.
JanelidzeSMattssonNPalmqvistS, et al.Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med2020; 26: 379–386.
6.
ThijssenEHLa JoieRStromA, et al.Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol2021; 20: 739–752.
7.
BatemanRJXiongCBenzingerTL, et al.Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med2012; 367: 795–804.
8.
SchindlerSEBollingerJGOvodV, et al.High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology2019; 93: e1647–e1659.
9.
PalmqvistSJanelidzeSStomrudE, et al.Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol2019; 76: 1060–1069.
10.
PalmqvistSJanelidzeSQuirozYT, et al.Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA2020; 324: 772–781.
11.
BrickmanAMManlyJJHonigLS, et al.Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement2021; 17: 1353–1364.
12.
BarthélemyNRBatemanRJHirtzC, et al.Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther2020; 12: 26.
13.
AltomareDStampacchiaSRibaldiF, et al.Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry2023; 94: 420–427.
14.
WilsonENYoungCBRamos BenitezJ, et al.Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimers Res Ther2022; 14: 172.
15.
GiuffrèGMQuarantaDVitaMG, et al.Performance of fully-automated high-throughput plasma biomarker assays for Alzheimer's disease in amnestic mild cognitive impairment subjects. J Prev Alzheimers Dis2024; 11: 1073–1078.
16.
JackCRJrBennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
17.
LeitãoMJSilva-SpínolaASantanaI, et al.Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther2019; 11: 91.
18.
RascovskyKHodgesJRKnopmanD, et al.Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain2011; 134: 2456–2477.
19.
Gorno-TempiniMLHillisAEWeintraubS, et al.Classification of primary progressive aphasia and its variants. Neurology2011; 76: 1006–1014.
20.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology2017; 89: 88–100.
21.
HöglingerGURespondekGStamelouM, et al.Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord2017; 32: 853–864.
22.
ArmstrongMJLitvanILangAE, et al.Criteria for the diagnosis of corticobasal degeneration. Neurology2013; 80: 496–503.
23.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
24.
FrisoniGBFestariCMassaF, et al.European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol2024; 23: 302–312.
25.
HanssonOBatrlaRBrixB, et al.The Alzheimer's association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement2021; 17: 1575–1582.
26.
O'BryantSEGuptaVHenriksenK, et al.Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement2015; 11: 549–560.
27.
NakamuraAKanekoNVillemagneVL, et al.High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature2018; 554: 249–254.
28.
BayoumySVerberkIMWden DulkB, et al.Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther2021; 13: 198.
29.
Montoliu-GayaLStrydomABlennowK, et al.Blood biomarkers for Alzheimer's disease in Down syndrome. J Clin Med2021; 10: 3639.
30.
MielkeMMDageJLFrankRD, et al.Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med2022; 28: 1398–1405.
31.
AshtonNJBrumWSDi MolfettaG, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol2024; 81: 255–263.
32.
CanoACapdevilaMPuertaR, et al.Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic. EBioMedicine2024; 108: 105345.
33.
ArranzJZhuNRubio-GuerraS, et al.Diagnostic performance of plasma pTau217, pTau181, Aβ1–42 and Aβ1–40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther2024; 16: 139.
34.
MendesAJRibaldiFLathuiliereA, et al.Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol2024; 271: 2053–2066.
35.
WinstonCNLangfordOLevinN, et al.Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's disease. J Alzheimers Dis2023; 92: 95–107.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
